Leadership & Pay · · GlobeNewswire
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
XLOXilio Therapeutics, Inc.
Xilio Therapeutics announced the appointment of Ben Harshbarger as chief legal officer. Harshbarger brings over 20 years of executive leadership and legal expertise in the biopharmaceutical industry, most recently serving as chief legal officer at Astria Therapeutics until its acquisition by BioCryst Pharmaceuticals. He previously held roles at Novelion Therapeutics, Aegerion Pharmaceuticals, Cubist Pharmaceuticals, ViaCell, and Biogen. Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer.